Compare AVAH & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAH | URGN |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2021 | 2016 |
| Metric | AVAH | URGN |
|---|---|---|
| Price | $12.30 | $26.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $15.05 | ★ $60.71 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1850.00 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $2,433,199,000.00 | $1,128,000.00 |
| Revenue This Year | $10.70 | $190.44 |
| Revenue Next Year | $7.63 | $69.25 |
| P/E Ratio | $22.90 | ★ N/A |
| Revenue Growth | ★ 20.19 | N/A |
| 52 Week Low | $5.93 | $16.50 |
| 52 Week High | $14.71 | $50.81 |
| Indicator | AVAH | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.70 | 29.46 |
| Support Level | $12.21 | $22.61 |
| Resistance Level | $13.76 | $27.76 |
| Average True Range (ATR) | 0.67 | 2.03 |
| MACD | -0.07 | -0.45 |
| Stochastic Oscillator | 8.54 | 20.19 |
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.